➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Dow
McKinsey
Johnson and Johnson
Mallinckrodt

Last Updated: July 9, 2020

DrugPatentWatch Database Preview

Litigation Details for Bayer Intellectual Property GmbH v. Aurobindo Pharma Limited (D. Del. 2015)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in Bayer Intellectual Property GmbH v. Aurobindo Pharma Limited
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Bayer Intellectual Property GmbH v. Aurobindo Pharma Limited (D. Del. 2015)

Date Filed Document No. Description Snippet Link To Document
2015-10-09 1 or more of U.S. Patent Nos. 7,157,456 (“the ’456 patent”), 7,585,860 (“the ’860 patent”), and 7,592,339… The ’456 Patent 84. United States Patent No. 7,157,456 (“the ’456 patent”), entitled… The ’860 Patent 90. United States Patent No. 7,585,860 (“the ’860 patent”), entitled… The ’339 Patent 96. United States Patent No. 7,592,339 (“the ’339 patent”), entitled… 1. This is an action for patent infringement under the patent laws of the United States, Title External link to document
2017-02-03 161 -6, 10, 14, 16, and 27 of U.S. Patent No. 7,157,456 (“the ’456 patent”), provided that the claim at issue…each of claims 8, 17, 18, 19, and 28 of the ’456 patent, provided that the claim at issue is not proven…infringes each of claims 7, 11, 20, and 21 of the ’456 patent, provided that the claim at issue is not proven…ingredient contained therein, infringe claim 1 of U.S. Patent No. 7,585,860, provided that the claim at issue…2015 13 July 2018 1:15-cv-00902 830 Patent None District Court, D. Delaware External link to document
2017-03-03 175 of a single term in U.S. Patent No. 7,157,456 ("the '456 patent"). The Court has considered…claim construction for a single term in U.S. Patent No. 7,157,456. Signed by Judge Richard G. Andrews on 3…infringe a number of Plaintiffs' patents. (D.I. 1). The patents-in-suit claim compounds for use in…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which …construing patent claims, a court considers the literal language of the claim, the patent specification External link to document
2017-04-24 219 § 271(e)(2) of U.S. Patent Nos. 7,157,456; 7,858,860; and 7,592,339 (the “patents-in-suit”); …Breckenridge as well with respect to the same patent or patents. 7. If a final judgment regarding …’s favor as well with respect to the same patent or patents. 8. Breckenridge and Plaintiffs retain…bound by the final judgment as it pertains to the patents-in-suit in the Action; and NOW THEREFORE…Action infringes any of the claims of the patents-in-suit, Breckenridge will be held to infringe External link to document
2017-05-04 230 -6, 10, 14, 16, and 27 of U.S. Patent No. 7,157,456 (“the ’456 patent”), provided that the claim at issue… infringement of the ’456 patent, the ’860 patent, and/or the ’339 patent. In addition, Plaintiffs will…and every claim of the ’456 patent, the ’860 patent, and the ’339 patent to which infringement is not… of any claim of the ’456 patent, the ’860 patent, and/or the ’339 patent. The parties…therein, infringe claim 1 of U.S. Patent No. 7,585,860 (“the ’860 patent”), provided that the claim at External link to document
2017-05-05 233 infringement of U.S. Patent Nos. 7,157,456; 7,585,860; and 7,592,339 (“the patents-in-suit”) under 35 …as well with respect to the same patent or patents. 7. If a final judgment regarding validity…’s favor as well with respect to the same patent or patents. 8. InvaGen and Plaintiffs retain the…bound by the final judgment as it pertains to the patents-in-suit in the Action; and Case 1:15-cv-00902-RGA…Action infringes any of the claims of the patents-in-suit, InvaGen will be held to infringe those External link to document
2018-07-13 317 Findings of Fact & Conclusions of Law infringement of claim 16 of U.S. Patent No. 7,157,456 (the “’456 patent”), which claims the compound rivaroxaban… ’456 patent and U.S. patent Nos. 7,585,860 (the “’860 patent”) and 7,592,339 (the “’339 patent”) were…of the ’456, ’860, and ’339 patents, including claim 16 of the ’456 patent. (Doc. Nos. 232, 236.) Plaintiffs…¶ 10.) B. The patent-in suit 7. The ’456 patent is entitled “Substituted Oxazolidinones…and is a named inventor on thirty (30) U.S. Patents and Patent Applications. (Defs. FF. ¶ 12 (citing 3/ External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Express Scripts
Johnson and Johnson
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.